Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$144.8 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 3513.76% year-over-year to -$144.8 million in Q1 2026; TTM through Mar 2026 was -$156.9 million, a 575.24% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, up 71.63% from the prior year.
• Cash from Investing Activities slipped to -$144.8 million in Q1 2026 per CRVS's latest filing, from $10.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $17.5 million in Q3 2023 and bottomed at -$144.8 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$2.6 million (2025), against an average of -$11.1 million.
• Across the five-year window, Cash from Investing Activities jumped 60714.29% in 2025 and sank 3513.76% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$3.9 million in 2022, then soared by 40.29% to -$2.3 million in 2023, then tumbled by 162.42% to -$6.1 million in 2024, then jumped by 278.86% to $10.9 million in 2025, then tumbled by 1431.31% to -$144.8 million in 2026.
• Per Business Quant, the three latest CRVS Cash from Investing Activities figures stand at -$144.8 million (Q1 2026), $10.9 million (Q4 2025), and -$2.6 million (Q3 2025).